Selecta Biosciences, Inc. (SELB) Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its stake in shares of Selecta Biosciences, Inc. (NASDAQ:SELB) by 2.2% during the third quarter, Holdings Channel reports. The firm owned 307,893 shares of the company’s stock after buying an additional 6,593 shares during the period. JPMorgan Chase & Co.’s holdings in Selecta Biosciences were worth $4,387,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Polaris Venture Management Co. V L.L.C. acquired a new position in shares of Selecta Biosciences during the second quarter worth about $26,919,000. Monashee Investment Management LLC acquired a new position in shares of Selecta Biosciences during the second quarter worth about $350,000. Vanguard Group Inc. acquired a new position in shares of Selecta Biosciences during the second quarter worth about $1,679,000. FMR LLC acquired a new position in shares of Selecta Biosciences during the second quarter worth about $3,997,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Selecta Biosciences during the second quarter worth about $6,296,000. 40.94% of the stock is currently owned by institutional investors and hedge funds.
Shares of Selecta Biosciences, Inc. (NASDAQ:SELB) opened at 15.17 on Friday. The firm has a 50-day moving average of $20.85 and a 200 day moving average of $16.14. Selecta Biosciences, Inc. has a 12-month low of $10.26 and a 12-month high of $28.00.
COPYRIGHT VIOLATION NOTICE: “Selecta Biosciences, Inc. (SELB) Shares Bought by JPMorgan Chase & Co.” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of U.S. and international copyright legislation. The correct version of this news story can be read at http://www.dailypolitical.com/2017/01/14/selecta-biosciences-inc-selb-shares-bought-by-jpmorgan-chase-co.html.
SELB has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Friday, December 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $32.00 price objective (up from $23.00) on shares of Selecta Biosciences in a research note on Thursday, December 8th. Finally, Canaccord Genuity set a $25.00 price objective on shares of Selecta Biosciences and gave the company a “buy” rating in a research note on Tuesday, December 6th.
In related news, insider Peter Keller sold 4,723 shares of the company’s stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $18.58, for a total transaction of $87,753.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Takashi Kei Kishimoto sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 28th. The stock was sold at an average price of $17.55, for a total transaction of $175,500.00. Following the transaction, the insider now owns 10,000 shares of the company’s stock, valued at $175,500. The disclosure for this sale can be found here.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences, Inc. (NASDAQ:SELB).
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.